Objective: Worthwhile interventions for intracerebral hemorrhage or subarachnoid hemorrhage generally hinge on whether they improve the odds of good outcome. Although good outcome is correlated with mobility, correlations with other domains of health-related quality of life, such as cognitive function and social functioning, are not well described. We tested the hypothesis that good outcome is more closely associated with mobility than other domains.
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For information regarding this article, E-mail: a-naidech@northwestern.edu able to independently ambulate or better, a de facto measure of mobility, and inclusive of all levels of cognitive and social function for ambulatory patients. Mobility is an important domain of health-related quality of life (HRQoL), but not the only one. Survivors of ICH and SAH may have impairments in cognitive function (CF, such as keeping track of appointments, managing financial affairs) (1), social functioning, and other domains. Cognition and social function are implied in the mRS with key questions regarding social function and ability to work. Previous investigations have used questionnaires such as the 136-question Sickness Impact Profile (1); while comprehensive, the time needed may be prohibitive.
Recognizing the importance of accurate assessment of HRQoL, the National Institutes of Health (NIH) supported the development of the Patient Reported Outcomes Measurement Information System (PROMIS) and Quality of Life in Neurological Disorders (Neuro-QOL) (2) . Despite their introduction (3), there are few data in survivors of ICH or SAH. Particular advantages include web-based assessment with computer adaptive testing, where each response affects the next question asked. We tested the hypothesis that good outcome would be higher for the domain of mobility than other specific domains of HRQoL.
MATERIALS AND METHODS

Patients
We prospectively enrolled consecutive patients from January 2011 through January 2014. All patients had a diagnosis of spontaneous ICH or SAH confirmed by a board-certified neurologist with head CT. Patients with trauma, hemorrhagic conversion of ischemic stroke, or structural lesions (e.g., tumor) were excluded. We approached patients or a legally authorized representative during the index hospitalization and asked for written consent to track identifiers and obtain outcomes, a preferred telephone number, and e-mail addresses. The study was approved by the Northwestern University Institutional Review Board. We recorded the medical history, severity of injury including the NIH Stroke Scale (NIHSS), and demographics.
mRS Assessment
The mRS is a validated scale from 0 (no symptoms) to 6 (death). A single interviewer (M.B.) obtained the mRS by validated interview at 1, 3, and 12 months (4). mRS scores were not given to respondents. For patients no longer in the hospital, the mRS was assessed by telephone interview, a commonly used method validated by others (1, (5) (6) (7) (8) . We defined "good outcome" as independence, mRS 0 through 3 versus 4 through 5, typical for outcome studies of patients with ICH (9) or SAH. (good outcome after acute ischemic stroke is usually more favorable, mRS 0 or 1 vs worse) (10) .
HRQoL Assessment
Our methods for obtaining HRQoL with Neuro-QOL have been previously described (11) . When Neuro-QOL became available for research use in January 2011, we obtained HRQoL at 1 and 3 months and follow-up at 12 months starting in late May 2011. Coincident with the mRS assessment, we sent an e-mail with a link to complete the HRQoL assessment, the usual method. Respondents could also answer HRQoL questions over the telephone with study staff (M.B.) performing proxy entry, recording answers on behalf of a patient or family member. We administered computer adaptive banks (12) in the following Neuro-QOL instruments: lower extremity function (mobility), CF-executive function (managing finances and household affairs), CF-general concerns (clarity of thinking and train of thought), and satisfaction with social roles and activities (SRA, ability to get work done, be with family). Computer adaptive testing algorithms ask questions at the predicted level of HRQoL until further data are unlikely to alter the estimate. Results are expressed in T scores, continuous numbers where the general U.S. population scores 50 ± 10. Further information on the algorithms, underlying iterative response theory, and detailed information about these and other available instruments is available at http://www.nihpromis.org and http://www.neuroqol.org.
Statistical Analysis
We tested the hypothesis that in analysis of receiver operating characteristic (ROC) curves, the area under the curve (AUC) would be different between domains of HRQoL. We assessed this by comparing the difference in AUC between curves and the corresponding z-value. The maximal sensitivity and specificity were ascertained from the ROC analytic tables. We compared normally distributed variables (e.g., T scores between the groups of good vs poor outcome) with t tests, whereas nonnormally distributed variables (NIHSS, length of stay, etc.) were compared with the U statistic. Statistical analysis was performed with NCSS v. 9 (NCSS; LLC, Kaysville, UT; http://www.ncss.com). A Neuro-QOL statistician who was not involved in the acquisition of data (J.L.B.) directed and reviewed the statistical analysis.
RESULTS
Patient Population
The demographics of the patients assessed at 1 month are shown in Table 1 . (Data for survivors assessed at 3 and 12 mo were similar.) We excluded 23 patients for whom we could not obtain HRQoL data, 23 patients for whom we could not obtain the mRS, 11 patients who died after hospital discharge, and three patients who were lost to follow-up and had neither mRS nor HRQoL data available. The sample was typical of patients with SAH and ICH in terms of age and historical rates of hypertension and diabetes. Compared with patients with good outcome, patients with poor outcome were older, had more comorbidities, had more severe neurologic injury on admit, and had a longer length of stay in the ICU and hospital.
Each instrument required a modest number of questions to estimate the T score, and this number of questions varied slightly. The computer adaptive test administered median 4 questions for CF-general concerns and satisfaction with SRA, median 5 questions for CF-executive function, and median 6 www.ccmjournal.org August 2015 • Volume 43 • Number 8 questions for mobility (p < 0.00001). Patients with poor outcome had worse HRQoL T scores (Table 1) , varying from 8.9 points (0.9 sd) in the domain of satisfaction with SRA to 22 points (2.2 sd) in the domain of mobility.
ROC curves are shown in the Figure 1 . Good outcome generally indicated T scores approximately 1.5 sd below the U.S. population mean, the value corresponding to the highest sensitivity and specificity for mRS 0 through 3 versus 4 through 5, Data were similar for the subset of patients who survived to 3 and 12 mo. Patients with poor outcome were more likely to have intracerebral hemorrhage rather than subarachnoid hemorrhage, be older, had greater severity of injury, longer length of stay, and lower health-related quality of life T score. Data are n (%), mean ± sd, or median (Q1-Q3) as appropriate. The Glasgow Coma Scale is score from 3 (unresponsive) to 15 (alert and oriented). The NIH Stroke Scale is score from 0 (normal) to 42 (worse possible score), with a score of 8 indicating a moderately severe deficit. T scores are normalized to the U.S. general population at 50 ± 10.
for example, the point on the ROC curve closest to the upper left corner of the curve. The AUC, optimal T score cutoff for distinguishing good versus poor outcome, and p value for comparison with mobility are shown in Table 2 . Results were similar when the time of outcome assessment was 3 or 12 months or whether good outcome was defined at 0 through 2 (moderate disability) versus 3 through 5, rather than 0 through 3 versus 4 through 5.
DISCUSSION
We found that continuous measures of domain-specific HRQoL distinguished between patients with good and poor outcome. These data add to the literature by using web-based computer adaptive testing and formal analysis of differences in AUC. AUC was different between specific domains, demonstrating that good outcome reflected mobility more than CF or SRA, both of which are important facets of HRQoL.
These data underscore the utility of the mRS as a global measure correlated with multiple domains of HRQoL, particularly mobility (13) . Patients who had good outcome had higher T scores in the domains of CF and satisfaction with SRA than patients with poor outcome. We used a typical definition of the mRS to define good outcome. As clinical outcomes scales are highly correlated with each other (14) , our results are likely to generalize to other outcome scales. Similarly, several NIH PROMIS instruments are highly correlated with Neuro-QOL, so one is likely to find similar results using the NIH PROMIS physical function instrument as opposed to the Neuro-QOL mobility instrument. Cross-walks between Neuro-QOL, PROMIS, and other validated outcome assessments are available at http://www.PROsettastone. org. More domains are available than the ones we assessed, and both SAH and ICH impair multiple domains of HRQoL in survivors. Future research might select other specific domains of particular interest for a given research hypothesis. NIH PROMIS and Neuro-QOL instruments are periodically updated, and scores from new instruments can be cross-walked to those from older instruments. This is part of the original mission of Neuro-QOL and PROMIS, crucial to obviate allegiance to outdated instruments for the sake of consistency over time.
Transitions from good to poor outcome were associated with large decreases in T scores. The ability to compare continuous numeric T scores rather than dichotomous categories may reduce type II error, particularly in domains that are not as well measured by the mRS and similar ordinal summary scores. A meaningful difference is generally regarded as 0.5 sd (15), or 5 points on the T score for the measures we describe here. In addition to a research setting, this might be helpful to assess the clinical status of patients or changes over time as we have previously described (11) .
Different domains of HRQoL may give complementary assessments of outcome. Previous investigations using multiple domain HRQoL assessments have also noted that good outcome is primarily defined by physical function (16) , although the AUC was not compared. It is important to be able to walk to the grocery store (mobility), but also important to be able to remember what to buy and pay the bill (CF), distinctions difficult to capture with a summary score.
We assessed HRQoL using web-based computer adaptive testing. This permits an algorithm to select questions likely to be most informative for a specific respondent during the assessment and avoids asking repeated questions that may be inappropriate. Once it is known a patient is nonambulatory, subsequent questions about walking do not improve the estimate of ability; adaptive tests query the respondent about easier tasks, such as sitting on the edge of a bed. Each domain was assessed in a median of only four to six questions. Unreliable computer adaptive tests would have been reflected in a high number of questions needed to estimate the T score for each domain and bias results toward the null hypothesis, not the results we found.
The designation of good outcome has a ceiling effect, discounting potential deficits in physical, social, and cognitive HRQoL (17) . Indeed, the optimal discrimination point of T scores for good outcome in ROC analysis was approximately 1.5 sd (15 points on the T score) below the U.S. population mean. Continuous T scores allow to compare the mean (or median) T score, a statistically more powerful comparison than comparing the odds of good outcome (15) , potentially decreasing the number of patients needed for clinical research and allowing to examine differences within the category of good outcome. One might assess Neuro-QOL or NIH PROMIS outcomes and compare T scores between groups for a primary endpoint, while other specific domains might be predefined secondary endpoints. High mortality might attenuate the advantages of measuring HRQoL as a primary endpoint, but mitigating this has been previously described (18) . Neuro-QOL and PROMIS may complement the mRS and be of particular interest in patients with at least some mobility.
We focused on domains that could be reliably assessed by the patient or a proxy. Neuro-QOL was validated for proxy report as part of its development, and we have previously noted that correcting for proxy report yields similar results (13) , particularly with regard to CF (11) . Other HRQoL scales have also been validated for proxy report (19, 20) . A potential limitation is that we did not perform specific neurocognitive testing to elucidate the cognitive impairments that underlie lower T scores for CF, and this is an opportunity for future research, specifically with standard assessments such as the NIH Toolbox (21) . We did not perform follow-up in person after hospital discharge, although the mRS has been validated for telephone assessment and vis-a-vis the in-person NIHSS (14) .
In this study, we focused on SAH and ICH, although our results are likely to apply to other critical illnesses. For example, acute respiratory distress syndrome impairs function years after illness, even for independent patients (22) . The advantages of Neuro-QOL and NIH PROMIS are also likely to apply.
In sum, we found that web-based computer adaptive testing for HRQoL reliably distinguished between good and poor outcomes. The AUC was greater for mobility than CF or satisfaction with SRA, underscoring that much clinical research necessarily focuses on mobility even when other domains may be of equivalent or greater interest. Measuring domain-specific HRQoL may provide an opportunity to make domain-specific improvements in outcome, such as improving CF alone, even if an outcome summary score would not change. Choosing continuous, domain-specific measures may allow for more patient-centered research. Mobility T scores were most closely associated with good outcome, although all were p < 0.0001. Results were similar for follow-up at 3 and 12 mo. A mobility T score of 35.8 had 92% sensitivity and 87% specificity for good outcome. Receiver operating characteristic curves are shown in Figure 1 .
